EP4288441A1 - Verfahren zur behandlung von spinocerebellarer ataxie typ 3 - Google Patents
Verfahren zur behandlung von spinocerebellarer ataxie typ 3Info
- Publication number
- EP4288441A1 EP4288441A1 EP22750319.0A EP22750319A EP4288441A1 EP 4288441 A1 EP4288441 A1 EP 4288441A1 EP 22750319 A EP22750319 A EP 22750319A EP 4288441 A1 EP4288441 A1 EP 4288441A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- pyrrolo
- pyrimidin
- chloro
- amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 152
- 208000002569 Machado-Joseph Disease Diseases 0.000 title claims abstract description 51
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 title claims abstract description 51
- 150000001875 compounds Chemical class 0.000 claims description 242
- -1 1H-pyrazolyl Chemical group 0.000 claims description 158
- 102000007371 Ataxin-3 Human genes 0.000 claims description 75
- 108010032947 Ataxin-3 Proteins 0.000 claims description 65
- 125000001424 substituent group Chemical group 0.000 claims description 55
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 49
- 108020004999 messenger RNA Proteins 0.000 claims description 48
- 150000003839 salts Chemical class 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 29
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- 239000012453 solvate Substances 0.000 claims description 18
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000002950 monocyclic group Chemical group 0.000 claims description 10
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 7
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- 229910052760 oxygen Inorganic materials 0.000 claims description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 3
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 claims description 2
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 claims description 2
- PSKYSEHRUFFTGT-UHFFFAOYSA-N 2,5-dichloro-N-(furan-2-ylmethyl)-6-[2-(methylamino)ethyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CNCCC1=C(C2=C(N1)N=C(N=C2NCC3=CC=CO3)Cl)Cl PSKYSEHRUFFTGT-UHFFFAOYSA-N 0.000 claims 2
- GFMRSNSEGHYHJL-QMMMGPOBSA-N 6-[(2S)-2-aminopropyl]-2,5-dichloro-N-(furan-2-ylmethyl)-7-methylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC1=C(C2=C(N=C(N=C2N1C)Cl)NCC3=CC=CO3)Cl)N GFMRSNSEGHYHJL-QMMMGPOBSA-N 0.000 claims 2
- UFHMMHHNICXIHM-QMMMGPOBSA-N C[C@@H](CC(N(C)C1=C2C(NCC(C=CN=C3)=C3F)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(N(C)C1=C2C(NCC(C=CN=C3)=C3F)=NC(Cl)=N1)=C2F)N UFHMMHHNICXIHM-QMMMGPOBSA-N 0.000 claims 2
- GLCLNUYMLXOXBP-QMMMGPOBSA-N C[C@@H](CC(N(C)C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(N(C)C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N GLCLNUYMLXOXBP-QMMMGPOBSA-N 0.000 claims 2
- CBZOAZFPLFOBFR-QMMMGPOBSA-N C[C@@H](CC(N(C)C1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(N(C)C1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)=C2F)N CBZOAZFPLFOBFR-QMMMGPOBSA-N 0.000 claims 2
- ITHBPSDTDFAXHV-VIFPVBQESA-N C[C@@H](CC(N(C)C1=C2C(NCC3=CC=NC=C3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(N(C)C1=C2C(NCC3=CC=NC=C3)=NC(Cl)=N1)=C2F)N ITHBPSDTDFAXHV-VIFPVBQESA-N 0.000 claims 2
- ADQWWHOMIXBGDS-ZETCQYMHSA-N C[C@@H](CC(N(C)C1=C2C(NCC3=NC=CS3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(N(C)C1=C2C(NCC3=NC=CS3)=NC(Cl)=N1)=C2F)N ADQWWHOMIXBGDS-ZETCQYMHSA-N 0.000 claims 2
- CSDULODIVUWONL-VIFPVBQESA-N C[C@@H](CC(N1C)=C(C)C(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1C)=C(C)C(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N CSDULODIVUWONL-VIFPVBQESA-N 0.000 claims 2
- MDWVNQMIOASMJB-ZETCQYMHSA-N C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N MDWVNQMIOASMJB-ZETCQYMHSA-N 0.000 claims 2
- CONIPZSQTZGMNC-FJXQXJEOSA-N C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N.Cl Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N.Cl CONIPZSQTZGMNC-FJXQXJEOSA-N 0.000 claims 2
- GILBZCPLODYJAV-UHFFFAOYSA-N 2-chloro-6-[2-(methylamino)ethyl]-N-(1,3-thiazol-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CNCCC1=CC2=C(N1)N=C(N=C2NCC3=NC=CS3)Cl GILBZCPLODYJAV-UHFFFAOYSA-N 0.000 claims 1
- HZSVFPWQGHPPBL-UHFFFAOYSA-N 2-chloro-N-(furan-2-ylmethyl)-6-[2-(methylamino)propyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC(CC1=CC2=C(N1)N=C(N=C2NCC3=CC=CO3)Cl)NC HZSVFPWQGHPPBL-UHFFFAOYSA-N 0.000 claims 1
- PHSLSNRUKIPEDG-UHFFFAOYSA-N 6-(3-aminopropyl)-2-chloro-N-(furan-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=COC(=C1)CNC2=NC(=NC3=C2C=C(N3)CCCN)Cl PHSLSNRUKIPEDG-UHFFFAOYSA-N 0.000 claims 1
- XBMDAINOZCOXGV-VIFPVBQESA-N 6-[(2S)-2-aminopropyl]-2-chloro-5-fluoro-7-methyl-N-(pyridin-2-ylmethyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1(Cl)=NC2=C(C(=C(C[C@@H](N)C)N2C)F)C(=N1)NCC1=NC=CC=C1 XBMDAINOZCOXGV-VIFPVBQESA-N 0.000 claims 1
- POFPNGCFSATMHG-VIFPVBQESA-N 6-[(2S)-2-aminopropyl]-2-chloro-5-fluoro-7-methyl-N-(pyridin-3-ylmethyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1(Cl)=NC=2N(C(C[C@H](C)N)=C(F)C=2C(=N1)NCC1=CC=CN=C1)C POFPNGCFSATMHG-VIFPVBQESA-N 0.000 claims 1
- BHIUNOBVDJXACB-QMMMGPOBSA-N 6-[(2S)-2-aminopropyl]-2-chloro-5-fluoro-N-(pyridin-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC1=C(C2=C(N1)N=C(N=C2NCC3=CC=CC=N3)Cl)F)N BHIUNOBVDJXACB-QMMMGPOBSA-N 0.000 claims 1
- GNXTXWHJAOFYFL-QMMMGPOBSA-N 6-[(2S)-2-aminopropyl]-2-chloro-5-fluoro-N-(pyridin-3-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1(Cl)=NC=2NC(C[C@H](C)N)=C(F)C=2C(=N1)NCC1=CC=CN=C1 GNXTXWHJAOFYFL-QMMMGPOBSA-N 0.000 claims 1
- BEYZUDIXQTUKAG-VIFPVBQESA-N 6-[(2S)-2-aminopropyl]-2-chloro-5-fluoro-N-[(2-fluorophenyl)methyl]-7-methylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC1=C(C2=C(N=C(N=C2N1C)Cl)NCC3=CC=CC=C3F)F)N BEYZUDIXQTUKAG-VIFPVBQESA-N 0.000 claims 1
- AFGOICKXYHIABN-QMMMGPOBSA-N 6-[(2S)-2-aminopropyl]-2-chloro-5-fluoro-N-[(2-fluorophenyl)methyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC1=C(C2=C(N1)N=C(N=C2NCC3=CC=CC=C3F)Cl)F)N AFGOICKXYHIABN-QMMMGPOBSA-N 0.000 claims 1
- NCXWPRHCSQTIHT-ZETCQYMHSA-N 6-[(2S)-2-aminopropyl]-2-chloro-N-(1,3-thiazol-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC1=CC2=C(N1)N=C(N=C2NCC3=NC=CS3)Cl)N NCXWPRHCSQTIHT-ZETCQYMHSA-N 0.000 claims 1
- NVNSCPIGMQOBPL-FJXQXJEOSA-N 6-[(2S)-2-aminopropyl]-2-chloro-N-(1,3-thiazol-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine hydrochloride Chemical compound C[C@@H](CC1=CC2=C(N1)N=C(N=C2NCC3=NC=CS3)Cl)N.Cl NVNSCPIGMQOBPL-FJXQXJEOSA-N 0.000 claims 1
- UTCGOGUWWOBQOE-QMMMGPOBSA-N 6-[(2S)-2-aminopropyl]-2-chloro-N-(thiophen-2-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC1=CC2=C(N1)N=C(N=C2NCC3=CC=CS3)Cl)N UTCGOGUWWOBQOE-QMMMGPOBSA-N 0.000 claims 1
- LAURDYZFLQTMQE-QMMMGPOBSA-N 6-[(2S)-2-aminopropyl]-5-fluoro-N-(furan-2-ylmethyl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(C)=N1)=C2F)N LAURDYZFLQTMQE-QMMMGPOBSA-N 0.000 claims 1
- CPHXFSIITJREKN-JTQLQIEISA-N 6-[(2S)-2-aminopropyl]-N-benzyl-2-chloro-5-fluoro-7-methylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C[C@@H](CC1=C(C2=C(N=C(N=C2N1C)Cl)NCC3=CC=CC=C3)F)N CPHXFSIITJREKN-JTQLQIEISA-N 0.000 claims 1
- DJUMWJQCGKPCRD-CYBMUJFWSA-N CC(C)(C)[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N Chemical compound CC(C)(C)[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N DJUMWJQCGKPCRD-CYBMUJFWSA-N 0.000 claims 1
- BTPFAJRZNRZKCC-CYBMUJFWSA-N CC(C)[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N Chemical compound CC(C)[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N BTPFAJRZNRZKCC-CYBMUJFWSA-N 0.000 claims 1
- RPSQRMQGPIYLPX-CQSZACIVSA-N CC(C)[C@@H](CC(N1)=CC(C(NCC2=CC=NC=C2)=N2)=C1N=C2Cl)N Chemical compound CC(C)[C@@H](CC(N1)=CC(C(NCC2=CC=NC=C2)=N2)=C1N=C2Cl)N RPSQRMQGPIYLPX-CQSZACIVSA-N 0.000 claims 1
- ORVGAIFXKYAFDY-SNVBAGLBSA-N CC(C)[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N Chemical compound CC(C)[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N ORVGAIFXKYAFDY-SNVBAGLBSA-N 0.000 claims 1
- BUKCMJHREDMQFS-LLVKDONJSA-N CC(C)[C@@H](CC(NC1=C2C(NCC3=CC=NC=C3)=NC(Cl)=N1)=C2F)N Chemical compound CC(C)[C@@H](CC(NC1=C2C(NCC3=CC=NC=C3)=NC(Cl)=N1)=C2F)N BUKCMJHREDMQFS-LLVKDONJSA-N 0.000 claims 1
- YEQORTATWMHFBO-NSHDSACASA-N CCCCC1=C(C[C@H](C)N)NC2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 Chemical compound CCCCC1=C(C[C@H](C)N)NC2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 YEQORTATWMHFBO-NSHDSACASA-N 0.000 claims 1
- JSORTGBAPBJEPL-VIFPVBQESA-N CCN(C(C[C@H](C)N)=C1F)C2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 Chemical compound CCN(C(C[C@H](C)N)=C1F)C2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 JSORTGBAPBJEPL-VIFPVBQESA-N 0.000 claims 1
- UIZUOJVXTJARNN-VIFPVBQESA-N CC[C@@H](CC(N(C)C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N Chemical compound CC[C@@H](CC(N(C)C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N UIZUOJVXTJARNN-VIFPVBQESA-N 0.000 claims 1
- OAOCFVXMKSOMCE-VIFPVBQESA-N CC[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N Chemical compound CC[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N OAOCFVXMKSOMCE-VIFPVBQESA-N 0.000 claims 1
- BSXKANZTHCDFEM-QMMMGPOBSA-N CC[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Cl)N Chemical compound CC[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Cl)N BSXKANZTHCDFEM-QMMMGPOBSA-N 0.000 claims 1
- HYXGTALZWQDBDS-QMMMGPOBSA-N CC[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N Chemical compound CC[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N HYXGTALZWQDBDS-QMMMGPOBSA-N 0.000 claims 1
- DPEJTCHFDGEERG-QMMMGPOBSA-N CC[C@@H](CC(NC1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)=C2F)N Chemical compound CC[C@@H](CC(NC1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)=C2F)N DPEJTCHFDGEERG-QMMMGPOBSA-N 0.000 claims 1
- GPWUVTHEQHACTD-ZETCQYMHSA-N CC[C@@H](CC(NC1=C2C(NCC3=NC=CS3)=NC(Cl)=N1)=C2F)N Chemical compound CC[C@@H](CC(NC1=C2C(NCC3=NC=CS3)=NC(Cl)=N1)=C2F)N GPWUVTHEQHACTD-ZETCQYMHSA-N 0.000 claims 1
- MRVFRHVUMDBXLU-IINYFYTJSA-N CC[C@H](C)[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N Chemical compound CC[C@H](C)[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N MRVFRHVUMDBXLU-IINYFYTJSA-N 0.000 claims 1
- MDTHBVGDTZGEEQ-MRVPVSSYSA-N CN(C(C[C@H](CO)N)=C1F)C2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 Chemical compound CN(C(C[C@H](CO)N)=C1F)C2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 MDTHBVGDTZGEEQ-MRVPVSSYSA-N 0.000 claims 1
- HHQYDLWUQIGRTF-SECBINFHSA-N CN(C(C[C@H](COC)N)=C1F)C2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 Chemical compound CN(C(C[C@H](COC)N)=C1F)C2=C1C(NCC1=CC=CO1)=NC(Cl)=N2 HHQYDLWUQIGRTF-SECBINFHSA-N 0.000 claims 1
- HQLIDFHPEXNGRF-UHFFFAOYSA-N CN(C)CCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl Chemical compound CN(C)CCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl HQLIDFHPEXNGRF-UHFFFAOYSA-N 0.000 claims 1
- LRLVFWJEWLXELS-UHFFFAOYSA-N CNCCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl Chemical compound CNCCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl LRLVFWJEWLXELS-UHFFFAOYSA-N 0.000 claims 1
- ANBFSNIDXKTFAV-UHFFFAOYSA-N CNCCC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Br Chemical compound CNCCC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Br ANBFSNIDXKTFAV-UHFFFAOYSA-N 0.000 claims 1
- ZISNGNAQSRKYKE-UHFFFAOYSA-N CNCCC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F Chemical compound CNCCC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F ZISNGNAQSRKYKE-UHFFFAOYSA-N 0.000 claims 1
- OUPIHKMXEJJCPZ-ZETCQYMHSA-N C[C@@H](CC(N(C)C1=C2C(NCC3=CN=CS3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(N(C)C1=C2C(NCC3=CN=CS3)=NC(Cl)=N1)=C2F)N OUPIHKMXEJJCPZ-ZETCQYMHSA-N 0.000 claims 1
- MAGKZTGPZSCJPA-LBPRGKRZSA-N C[C@@H](CC(N(C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)C(C=C1)=CC=C1OC)=C2F)N Chemical compound C[C@@H](CC(N(C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)C(C=C1)=CC=C1OC)=C2F)N MAGKZTGPZSCJPA-LBPRGKRZSA-N 0.000 claims 1
- SQHIOABPLJSVOB-LBPRGKRZSA-N C[C@@H](CC(N(C1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)C(C=C1)=CC=C1OC)=C2F)N Chemical compound C[C@@H](CC(N(C1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)C(C=C1)=CC=C1OC)=C2F)N SQHIOABPLJSVOB-LBPRGKRZSA-N 0.000 claims 1
- PEOOVXLJDBRZFR-QMMMGPOBSA-N C[C@@H](CC(N1)=C(C)C(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1)=C(C)C(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N PEOOVXLJDBRZFR-QMMMGPOBSA-N 0.000 claims 1
- YNRKYUHEUMSMKV-QMMMGPOBSA-N C[C@@H](CC(N1)=CC(C(NCC(C=CN=C2)=C2F)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1)=CC(C(NCC(C=CN=C2)=C2F)=N2)=C1N=C2Cl)N YNRKYUHEUMSMKV-QMMMGPOBSA-N 0.000 claims 1
- HJWJOOGEVYSVQH-QMMMGPOBSA-N C[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl)N HJWJOOGEVYSVQH-QMMMGPOBSA-N 0.000 claims 1
- GLIZMKQPYDXCDO-VIFPVBQESA-N C[C@@H](CC(N1)=CC(C(NCC2=CC=NC=C2)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1)=CC(C(NCC2=CC=NC=C2)=N2)=C1N=C2Cl)N GLIZMKQPYDXCDO-VIFPVBQESA-N 0.000 claims 1
- JCCQSCAOYZSDKL-QMMMGPOBSA-N C[C@@H](CC(N1)=CC(C(NCC2=COC=C2)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1)=CC(C(NCC2=COC=C2)=N2)=C1N=C2Cl)N JCCQSCAOYZSDKL-QMMMGPOBSA-N 0.000 claims 1
- VSLYHMJIMWKNOK-ZETCQYMHSA-N C[C@@H](CC(N1)=CC(C(NCC2=CSC=N2)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1)=CC(C(NCC2=CSC=N2)=N2)=C1N=C2Cl)N VSLYHMJIMWKNOK-ZETCQYMHSA-N 0.000 claims 1
- PJBJDAUQQXPPHG-ZETCQYMHSA-N C[C@@H](CC(N1)=CC(C(NCC2=NC=CO2)=N2)=C1N=C2Cl)N Chemical compound C[C@@H](CC(N1)=CC(C(NCC2=NC=CO2)=N2)=C1N=C2Cl)N PJBJDAUQQXPPHG-ZETCQYMHSA-N 0.000 claims 1
- CTEHFRPVCJDRBM-VIFPVBQESA-N C[C@@H](CC(NC1=C2C(NCC3=CC=CC=C3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CC=C3)=NC(Cl)=N1)=C2F)N CTEHFRPVCJDRBM-VIFPVBQESA-N 0.000 claims 1
- WSROKGDODBCLPB-ZETCQYMHSA-N C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Br)=N1)=C2F)N Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Br)=N1)=C2F)N WSROKGDODBCLPB-ZETCQYMHSA-N 0.000 claims 1
- XXEBFMJANMFKGL-ZETCQYMHSA-N C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Br)N Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Br)N XXEBFMJANMFKGL-ZETCQYMHSA-N 0.000 claims 1
- DJQJNYVLYDVYGU-ZETCQYMHSA-N C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Cl)N Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2Cl)N DJQJNYVLYDVYGU-ZETCQYMHSA-N 0.000 claims 1
- FOCWHMNEHOTLKK-ZETCQYMHSA-N C[C@@H](CC(NC1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(NC1=C2C(NCC3=CC=CS3)=NC(Cl)=N1)=C2F)N FOCWHMNEHOTLKK-ZETCQYMHSA-N 0.000 claims 1
- AFAYTXKSCCFRNR-LURJTMIESA-N C[C@@H](CC(NC1=C2C(NCC3=NC=CS3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@@H](CC(NC1=C2C(NCC3=NC=CS3)=NC(Cl)=N1)=C2F)N AFAYTXKSCCFRNR-LURJTMIESA-N 0.000 claims 1
- GLCLNUYMLXOXBP-MRVPVSSYSA-N C[C@H](CC(N(C)C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N Chemical compound C[C@H](CC(N(C)C1=C2C(NCC3=CC=CO3)=NC(Cl)=N1)=C2F)N GLCLNUYMLXOXBP-MRVPVSSYSA-N 0.000 claims 1
- IDEFMLBFLJAFDR-UHFFFAOYSA-N NCCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl Chemical compound NCCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl IDEFMLBFLJAFDR-UHFFFAOYSA-N 0.000 claims 1
- XZNMGYDEYADSTQ-UHFFFAOYSA-N NCCCC(NC1=NC(Cl)=NC(NCC2=CC=CO2)=C11)=C1F Chemical compound NCCCC(NC1=NC(Cl)=NC(NCC2=CC=CO2)=C11)=C1F XZNMGYDEYADSTQ-UHFFFAOYSA-N 0.000 claims 1
- LRLVFWJEWLXELS-FIBGUPNXSA-N [2H]C([2H])([2H])NCCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl Chemical compound [2H]C([2H])([2H])NCCC(N1)=CC(C(NCC2=CC=CO2)=N2)=C1N=C2Cl LRLVFWJEWLXELS-FIBGUPNXSA-N 0.000 claims 1
- XXHGDLJQCZLECB-UHFFFAOYSA-N pyrimidin-4-amine;hydrochloride Chemical compound Cl.NC1=CC=NC=N1 XXHGDLJQCZLECB-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 8
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 46
- 230000003247 decreasing effect Effects 0.000 description 30
- 150000003254 radicals Chemical class 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 201000010099 disease Diseases 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 15
- 238000001727 in vivo Methods 0.000 description 14
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 14
- 102000008300 Mutant Proteins Human genes 0.000 description 13
- 108010021466 Mutant Proteins Proteins 0.000 description 13
- 239000000651 prodrug Substances 0.000 description 12
- 229940002612 prodrug Drugs 0.000 description 12
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000894007 species Species 0.000 description 11
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 8
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 125000001246 bromo group Chemical group Br* 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004958 brain cell Anatomy 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 210000002064 heart cell Anatomy 0.000 description 5
- 210000003292 kidney cell Anatomy 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000005229 liver cell Anatomy 0.000 description 5
- 210000005265 lung cell Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 210000000663 muscle cell Anatomy 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 125000002346 iodo group Chemical group I* 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 239000008177 pharmaceutical agent Substances 0.000 description 4
- 108010040003 polyglutamine Proteins 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 210000003497 sciatic nerve Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000003901 trigeminal nerve Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 3
- 101000813117 Homo sapiens Elongator complex protein 1 Proteins 0.000 description 3
- 108020004485 Nonsense Codon Proteins 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000012084 conversion product Substances 0.000 description 3
- 125000004431 deuterium atom Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 125000001041 indolyl group Chemical group 0.000 description 3
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 3
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 101150074725 Atxn3 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000001730 Familial dysautonomia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 201000001638 Riley-Day syndrome Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 150000001447 alkali salts Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000012059 conventional drug carrier Substances 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- PAORVUMOXXAMPL-SECBINFHSA-N (2s)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl chloride Chemical compound CO[C@](C(Cl)=O)(C(F)(F)F)C1=CC=CC=C1 PAORVUMOXXAMPL-SECBINFHSA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 description 1
- 125000001359 1,2,3-triazol-4-yl group Chemical group [H]N1N=NC([*])=C1[H] 0.000 description 1
- 125000001506 1,2,3-triazol-5-yl group Chemical group [H]N1N=NC([H])=C1[*] 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- 125000005877 1,4-benzodioxanyl group Chemical group 0.000 description 1
- 125000005960 1,4-diazepanyl group Chemical group 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 125000005955 1H-indazolyl group Chemical group 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JAAXPOGNLKNTBW-UHFFFAOYSA-N 2-chloro-N-(pyridin-4-ylmethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound ClC1=NC2=C(C=CN2)C(NCC2=CC=NC=C2)=N1 JAAXPOGNLKNTBW-UHFFFAOYSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000384062 Armadillo Species 0.000 description 1
- 102000016904 Armadillo Domain Proteins Human genes 0.000 description 1
- 108010014223 Armadillo Domain Proteins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028347 Muscle twitching Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000288961 Saguinus imperator Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000028752 abnormal posture Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002313 adhesive film Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000004533 benzofuran-5-yl group Chemical group O1C=CC2=C1C=CC(=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 150000005347 biaryls Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011979 disease modifying therapy Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000029444 double vision Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 208000001936 exophthalmos Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 1
- 125000002140 imidazol-4-yl group Chemical group [H]N1C([H])=NC([*])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- RCRODHONKLSMIF-UHFFFAOYSA-N isosuberenol Natural products O1C(=O)C=CC2=C1C=C(OC)C(CC(O)C(C)=C)=C2 RCRODHONKLSMIF-UHFFFAOYSA-N 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000005969 isothiazolinyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 description 1
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 1
- 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- QANMHLXAZMSUEX-UHFFFAOYSA-N kinetin Chemical class N=1C=NC=2N=CNC=2C=1NCC1=CC=CO1 QANMHLXAZMSUEX-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- VHWYCFISAQVCCP-UHFFFAOYSA-N methoxymethanol Chemical compound COCO VHWYCFISAQVCCP-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
- 125000005882 oxadiazolinyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004299 tetrazol-5-yl group Chemical group [H]N1N=NC(*)=N1 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
- 125000005305 thiadiazolinyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000005310 triazolidinyl group Chemical group N1(NNCC1)* 0.000 description 1
- 125000005881 triazolinyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical class OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163146139P | 2021-02-05 | 2021-02-05 | |
| PCT/US2022/014929 WO2022169864A1 (en) | 2021-02-05 | 2022-02-02 | Methods for treating spinocerebellar ataxia type 3 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP4288441A1 true EP4288441A1 (de) | 2023-12-13 |
Family
ID=82742475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP22750319.0A Pending EP4288441A1 (de) | 2021-02-05 | 2022-02-02 | Verfahren zur behandlung von spinocerebellarer ataxie typ 3 |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4288441A1 (de) |
| WO (1) | WO2022169864A1 (de) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4115882A1 (de) * | 2015-01-16 | 2023-01-11 | The General Hospital Corporation | Verbindungen zur verbesserung des spleissens von mrna |
| CN110300590A (zh) * | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| EP3924050A1 (de) * | 2019-02-13 | 2021-12-22 | PTC Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidinverbindungen zur behandlung von familiärer dysautonomie |
-
2022
- 2022-02-02 WO PCT/US2022/014929 patent/WO2022169864A1/en active Application Filing
- 2022-02-02 EP EP22750319.0A patent/EP4288441A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022169864A1 (en) | 2022-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220135586A1 (en) | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | |
| CN115175679A (zh) | 治疗雌激素受体相关疾病的方法 | |
| CA3119656A1 (en) | Macrocyclic compounds and their use in the treatment of disease | |
| US20210177846A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
| US20230138663A1 (en) | Eaat2 activators and methods of using thereof | |
| US20190040040A1 (en) | Pyridazine derivatives as eaat2 activators | |
| US20220135568A1 (en) | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia | |
| US20210269442A1 (en) | Fused ring derivative used as fgfr4 inhibitor | |
| US11377436B2 (en) | EAAT2 enhancing molecules | |
| US20220315536A1 (en) | Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof | |
| WO2022169864A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| US20240041886A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| WO2022169868A1 (en) | Compounds for treating spinocerebellar ataxia type 3 | |
| CA3230996A1 (en) | Methods for treating neurogenerative diseases | |
| US20240018146A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| WO2023283373A1 (en) | 3,4-methylenedioxymethamphetamine and related psychedlics and uses thereof | |
| US20240051968A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| WO2023039370A1 (en) | Methods for treating neurogenerative diseases | |
| WO2023039369A1 (en) | Methods for treating neurogenerative diseases | |
| CN118019531A (en) | Methods for treating neurodegenerative diseases | |
| WO2023250316A1 (en) | Compounds for treating spinocerebellar ataxia type 3 | |
| US20230057568A1 (en) | Compounds for treating familial dysautonomia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20230803 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |